AbbVie Inc. (ETR: 4AB)
Germany
· Delayed Price · Currency is EUR | Market Cap | 297.86B |
| Revenue (ttm) | 49.79B |
| Net Income (ttm) | 4.56B |
| Shares Out | n/a |
| EPS (ttm) | 2.57 |
| PE Ratio | 65.38 |
| Forward PE | n/a |
| Dividend | 5.70 (3.44%) |
| Ex-Dividend Date | Jan 15, 2025 |
| Volume | 1,009 |
| Open | 166.18 |
| Previous Close | 165.92 |
| Day's Range | 164.50 - 166.18 |
| 52-Week Range | 137.80 - 192.50 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 31, 2025 |
About AbbVie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E... [Read more]
Financial Performance
In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.82 billion, a decrease of -59.09%.
Financial numbers in USD Financial StatementsNews
Kevin K Buckbee Executes Sell Order: Offloads $310K In AbbVie Stock
On December 18, a recent SEC filing unveiled that Kevin K Buckbee , SVP at AbbVie (NYSE: ABBV) made an insider sell. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on...
Retirement-Ready Income: 5 Dividend Gems I'd Buy If I Were 65
Dividend investing can provide reliable income and peace of mind in retirement. I share five standout picks perfect for a retirement-ready portfolio. These stocks offer strong yields, consistent growt...
My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys
In November, I invested $1,400 primarily in Business Development Companies, boosting my yearly dividend income by $148, with a YTD total exceeding $1,400. My portfolio achieved all-time highs, driven ...
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo; Topic is Pharmacokinetics of AL001.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock.
Why Investors Should Watch AbbVie Inc (ABBV)
AbbVie Inc is a global biopharmaceutical company that specializes in the discovery, development, manufacturing, and marketing of advanced medicines. AbbVie focuses primarily on immunology, oncology, n...
AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors
AbbVie is a strong investment opportunity with growth potential, dividend income, and a diverse drug portfolio. Find out why ABBV stock is a Buy.
AbbVie (ABBV) Acquires Nimble Therapeutics for $200 Million
AbbVie (ABBV) Acquires Nimble Therapeutics for $200 Million
AbbVie Enters Oversold Territory
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important ...
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "M...
AbbVie (ABBV) Announces Leadership Transition in Financial Department
AbbVie (ABBV) Announces Leadership Transition in Financial Department
AbbVie to acquire Roche spinout Nimble for $200M upfront
AbbVie (ABBV) has agreed to acquire Roche spinout and psoriasis drug developer Nimble Therapeutics for $200M upfront. Read more here.
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across autoim...
Buy 6 December Dividend Kings But Watch 22 With 'Safer' Dividends
"A Dividend King [is] a stock with 50 or more consecutive years of dividend increases." - suredividend.com. 53 Divided Kings, screened as of December 11, 2024, represented all eleven Morningstar Secto...
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
ATLANTA--(BUSINESS WIRE)---- $ABBV #5_clinical_trials_to_start_2025--Alzamend Neuro Reports 2nd Quarter 2025 Financial Results and Provides Update on Clinical Programs; Cash of $4.1 million as of Octo...
Betting Big On AbbVie: A Prescription For Growth And Dividends
AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find out why ABBV stock is a Buy.
AbbVie Completes Acquisition of Aliada Therapeutics
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline and R...
Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends
"Dividend Aristocrats
Dividend Income Summary: Lanny's November 2024 Summary
Investing in dividend stocks allows you to earn dividend income, the best passive income stream. The power of compounding and dividend reinvestment is a wonderful component to the portfolio. All of th...
AbbVie Inc (ABBV) Announces Promising Clinical Trial Results for Epcoritamab in Treating ...
AbbVie Inc (ABBV) Announces Promising Clinical Trial Results for Epcoritamab in Treating Diffuse Large B-Cell Lymphoma
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill. , Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new results ...
AbbVie reports Phase 3 data for tavapadon in Parkinson's disease
AbbVie (ABBV) reported positive topline results from a Phase 3 study of its drug tavapadon in the treatment of early Parkinson’s disease. Read more here.
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
On Monday, AbbVie Inc. (NYSE: ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monotherapy in early Parkinson's dise...
AbbVie’s third successful Parkinson’s trial sets the stage for an eventful 2025
AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said it’s on track to seek approval for the drug from the Food and Drug Administr...